Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Precision Medicine Offers Belatacept Monotherapy
NCT02939365 · University of California, San Francisco · PHASE4 · withdrawn · last registry update 2022-12-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Because of inability to get FDA approval for” | – | Registry record, University of California, San Francisco |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD86 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-04Also stopped (withdrawn): National Institute of Allergy and Infectious Diseases (NIAID), abatacept (NCT03733067)
- 2023-12-04Results posted on the registry: Massachusetts General Hospital, Immunosuppression reduction (NCT04177095)
- 2023-11-08Results posted on the registry: NYU Langone Health, Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention (NCT04503616)
- 2023-10-10Results posted on the registry: Amgen, Belatacept + VIB4920 (NCT04046549)
- 2023-05-08Results posted on the registry: Columbia University, Abatacept + Adalimumab (NCT03619876)
- 2023-05-08Also stopped (terminated): Columbia University, Abatacept + Adalimumab (NCT03619876)
- 2023-04-21Results posted on the registry: Daniel Benjamin, Infliximab + Abatacept (NCT04593940)
- 2023-02-06Results posted on the registry: NYU Langone Health, Abatacept + DMARDs (NCT03652961)
- 2022-12-13Results posted on the registry: University of California, Los Angeles, Belatacept (NCT01953120)
- 2022-11-09Results posted on the registry: Brigham and Women's Hospital, Belatacept (NCT02327403)
- 2022-10-07Results posted on the registry: Bristol-Myers Squibb, Abatacept (NCT04472494)
- 2022-10-07Also stopped (terminated): Bristol-Myers Squibb, Abatacept (NCT04472494)
- 2022-10-03Phase 3 first posted: Nantes University Hospital, Belatacept 250 Milligram Intravenous Powder for Solution (NCT05562869)
- 2022-08-29Results posted on the registry: George Washington University, Abatacept (NCT02594735)
- 2022-08-25Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor (NCT05515029)
- 2022-07-11Phase 3 first posted: Zhejiang Provincial People's Hospital, Janus Kinase Inhibitor + Abatacept (NCT05451615)
- 2022-06-23Phase 3 first posted: University Hospital, Montpellier, Abatacept (W12-W48) + TNF Inhibitor (W12-W48) (NCT05428488)
- 2022-04-20Phase 3 first posted: Massachusetts General Hospital, Abatacept plus + Placebo (NCT05335928)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision